Literature DB >> 18070292

Views of hepatitis C virus patients delayed from treatment for psychiatric reasons.

P J Rowan1, N J Dunn, H B El-Serag, M E Kunik.   

Abstract

For patients with chronic hepatitis C virus, certain psychiatric disorders are contraindications for antiviral therapy with interferon-alpha (IFN). Although these conditions delay a significant portion of patients from beginning therapy, no one has yet portrayed the views of these patients. A qualitative analysis, drawing upon semi-structured interviews, was developed to generate hypotheses regarding patient views of the treatment disposition process, and to generate strategies for increasing the portion of treatment-eligible patients. Two focus groups were conducted: one for patients delayed from treatment due to current or recent depression, and one for patients delayed due to current or recent alcohol use. A grounded theory analysis of the interview data were conducted. Patients were generally satisfied with the decision-making process, based largely on education from, and trust in, physicians. Upon learning their diagnosis, patients reported making healthy behaviour changes regarding alcohol, diet, exercise and herbal remedies. Some patients reported that requiring a period of alcohol abstinence was excessive, as they believed that they could discontinue alcohol use immediately, if so instructed by a physician. Patients seemed to over-interpret the likelihood of suicide during interferon-alpha (IFN) therapy. Current or recent psychiatric morbidity delays many patients from beginning interferon therapy. Nonetheless, this may be an optimal time for physicians to encourage healthy behaviours including abstinence from alcohol. Also, physicians may need to extensively assess the use of herbal remedies by patients. To help patients make judgments about beginning therapy, physicians should focus upon risk communication regarding the likelihood of suicide on therapy with interferon.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070292     DOI: 10.1111/j.1365-2893.2007.00884.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  7 in total

Review 1.  What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments?

Authors:  Paul J Rowan
Journal:  World J Virol       Date:  2015-02-12

2.  Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers.

Authors:  Donna M Evon; Carol E Golin; Jason E Bonner; Catherine Grodensky; Jennifer Velloza
Journal:  J Clin Gastroenterol       Date:  2015 May-Jun       Impact factor: 3.062

3.  10-year trends in the diagnosis and treatment of hepatitis C and concomitant mental health disorders: 1995 to 2005.

Authors:  Barbara P Yawn; Liliana Gazzuola Rocca; Peter C Wollan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 4.  Review of patient-reported outcome measures in chronic hepatitis C.

Authors:  Leah Kleinman; Sally Mannix; Yong Yuan; Shannon Kummer; Gilbert L'Italien; Dennis Revicki
Journal:  Health Qual Life Outcomes       Date:  2012-08-07       Impact factor: 3.186

5.  Re-designing Orem's Self-care Theory for Patients with Chronic Hepatitis.

Authors:  Ali Hasanpour-Dehkordi; Nooredin Mohammadi; Alireza Nikbakht-Nasrabadi
Journal:  Indian J Palliat Care       Date:  2016 Oct-Dec

6.  Peripheral Organs of Dengue Fatal Cases Present Strong Pro-Inflammatory Response with Participation of IFN-Gamma-, TNF-Alpha- and RANTES-Producing Cells.

Authors:  Tiago F Póvoa; Edson R A Oliveira; Carlos A Basílio-de-Oliveira; Gerard J Nuovo; Vera L A Chagas; Natália G Salomão; Ada Maria de Barcelos Alves; Ester M Mota; Marciano V Paes
Journal:  PLoS One       Date:  2016-12-22       Impact factor: 3.240

7.  Assessment of Educational Needs and Quality of Life of Chronic Hepatitis Patients.

Authors:  Ming-Chuan Chen; Hung-Chang Hung; Hsiu-Ju Chang; Sheng-Shun Yang; Wen-Chen Tsai; Shu-Chuan Chang
Journal:  BMC Health Serv Res       Date:  2017-02-17       Impact factor: 2.655

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.